Epoch Biodesign
Develops biological recycling processes and commercial plants to break down and recover nylon 6.6 waste for circular material supply chains.
Overview
Epoch Biodesign develops biological recycling processes and commercial biorecycling plants to process nylon 6.6 waste, aiming to recover materials for circular supply chains. The company is focused on industrial-scale solutions within the polymer recycling market and positions its facilities as alternatives to mechanical or petrochemical routes for end-of-life nylon 6.6. Based in London, Epoch raised £9M from Extantia and Kompas VC in an undisclosed round announced 25 March 2026 to fund its largest nylon 6.6 biorecycling plant. The financing brings total disclosed capital to $13M across one round and is intended to support scale-up and plant deployment.
Funding History
London’s Epoch Biodesign raises £9M from Extantia and Kompas VC for its largest nylon 6.6 biorecycling plant
Frequently Asked Questions
- How much has Epoch Biodesign raised in total?
- Epoch Biodesign has raised a total of $13M across 1 funding round.
- Who are Epoch Biodesign's investors?
- Epoch Biodesign's investors include Undisclosed.
- What does Epoch Biodesign do?
- Epoch Biodesign develops biological recycling processes and commercial biorecycling plants to process nylon 6.6 waste, aiming to recover materials for circular supply chains. The company is focused on industrial-scale solutions within the polymer recycling market and positions its facilities as alternatives to mechanical or petrochemical routes for end-of-life nylon 6.6. Based in London, Epoch raised £9M from Extantia and Kompas VC in an undisclosed round announced 25 March 2026 to fund its largest nylon 6.6 biorecycling plant. The financing brings total disclosed capital to $13M across one round and is intended to support scale-up and plant deployment.
- Where is Epoch Biodesign headquartered?
- Epoch Biodesign is headquartered in London, UK.
Investors
Related Insights
The definitive guide to AI startup funding in 2026 — from pre-seed through IPO, covering valuation mechanics, timelines, investor expectations, and how AI companies differ from traditional tech startups.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.